All posts by: Michael Zand

About Michael Zand

Zach Hartman, PhD Positions For 2018: Oncology And Immunotherapy In Focus – Seeking Alpha

Continue reading

2017-12-30 NEWS

Zach Hartman, PhD Positions For 2018: Oncology And Immunotherapy In Focus
Seeking Alpha
Cell therapy is going to be a big factor in 2018, with companies like Gilead and Juno Therapeutics leading the charge. Gene therapies have also been boiling in the kettle in 2017, and we’re almost certain to see some of our first approvals for viral

and more »

Continue reading

2017-12-30 NEWS

OZY

CRISPR’s About to Get a Massive Upgrade
OZY
Welcome to 2018: Research teams around the world are looking beyond CRISPR, DNA editing tech’s first generation, to the next leaps forward. Those include the potential to transform nucleotides, which could correct mutations, anti-CRISPR proteins that